MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ADHD (MTA)

多动症儿童的多模式治疗研究 (MTA)

• 批准号: 2034010
• 负责人: STEPHEN HINSHAW
• 金额: $ 55.37万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 1998-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2034010
• 关键词: academic achievement; amphetamines; attention deficit disorder; behavior modification; behavior test; behavioral /social science research tag; central nervous system stimulants; child behavior; clinical research; cognitive behavior therapy; cooperative study; disease /disorder proneness /risk; family structure /dynamics; human subject; human therapy evaluation; interpersonal relations; interview; longitudinal human study; mental disorder chemotherapy; mental disorder diagnosis; methylphenidate; middle childhood (6-11); neuropsychological tests; parent offspring interaction; pediatric pharmacology; peer group; play; problem solving; psychometrics; psychotherapy; questionnaires; social behavior; substance abuse related disorder

This Competing Continuation Application requests funding for Years 06 to 10 of the NIMH collaborative Multimodal Treatment Study of Children with Attention-Deficit Hyperactivity Disorder (MTA Study). In a parallel-group design, 576 rigorously diagnosed children with ADHD (96 at each of 6 sites), age 7-9, are randomly assigned to four treatment conditions: (1) Medication-only; (2) Psychosocial-only; (3) Combined (medication & psychosocial); or (4) Assessment-and- Referral-only. All but the latter are treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post- treatment) follow-up at 24 months, but insufficient funds and time prevented longer-term follow-up. This Continuation request, in concert with the companion Competing Supplement for Year 05, would begin the longer-term follow-up of differential treatment effects by following all subjects at least through their 5th year (4 yr post-treatment). Continuation Aim 1 is to conduct confirmatory tests of the hypothesis that a Combined Treatment strategy is significantly more effective in producing long-term therapeutic gains and preventing new psycho pathology than Medication or Psychosocial-treatment alone and that the difference is clinically meaningful. Continuation Aim 2 is to conduct confirmatory tests of the hypothesis that systematic, intensive treatments (all 3 active MTA treatments) are significantly more effective (statistically and clinically) in producing long-term therapeutic gains and preventing new psychopathology than treatments typically received in the community. Continuation Aim 3 is to conduct confirmatory tests of the hypothesis that systematic treatments for ADHD in early childhood alter the risk for subsequent patterns of substance use and abuse and that the risk alteration is clinically significant. Continuation Aim 4 is to conduct exploratory analyses to determine whether pre-treatment individual differences (severity, comorbidity, parent functioning, family history) are associated with patterns of stability/change in treatment effects. Continuation Aim 5 is to conduct exploratory analyses to determine the extent to which patterns of stability/change in therapeutic attitudes or attributions and in treatment-related behaviors vary as a function of randomly assigned treatment, pre- or post-treatment differences in functioning, post- treatment reports of satisfaction, and preexisting characteristics.

该竞争连续申请多年来要求资金 NIMH协作多模式治疗研究的06至10 注意力缺陷多动障碍的儿童（MTA研究）。 在平行组的设计中，有576个严格诊断为患有的儿童 ADHD（6个站点中的每个96），7-9岁，随机分配给四个 治疗条件：（1）仅用药； （2）仅心理社会； （3） 合并（药物与社会心理）；或（4）评估和 - 仅转介。除后者以外的所有人都经过深入处理14个月， 对基线，3、9、14和24个月的所有受试者进行评估。 因此，原始的MTA设计提供了短期（10个月后 - 治疗）在24个月的后续行动，但资金和时间不足 防止长期随访。这个延续要求，演唱会 随着同伴竞争的补充05年，将开始 通过遵循差异治疗效应的长期随访 所有受试者至少在第五年（治疗后4年）。 持续目的1是对假设进行验证测试 联合治疗策略在 产生长期的治疗成就并防止新的心理 病理学比单独的药物或心理社会治疗 区别在临床上是有意义的。继续目标2是 对系统密集型的假设进行验证性测试 治疗（所有3种活跃的MTA治疗）明显更多 有效（统计和临床上）产生长期治疗 比治疗通常 在社区中收到。继续目标3是进行 关于系统治疗的假设的确认性测试 幼儿时期的多动症改变了随后模式的风险 药物使用和滥用，风险改变在临床上 重要的。持续目标4是进行探索性分析 确定治疗前是否存在个体差异（严重程度， 合并症，父母功能，家族史）与 治疗效果的稳定性/变化模式。连续目标5是 进行探索性分析以确定 治疗态度或归因的稳定性/变化模式 在治疗相关的行为中，随机分配的函数各不相同 治疗，治疗前或治疗后的功能差异 满意度和特征的治疗报告。